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Abstract
Dysfunctions of MeCP2 protein lead to various neurological disorders such as Rett syn-
drome and Autism. The exact functions of MeCP2 protein is still far from clear. At a molecu-
lar level, there exist contradictory data. MeCP2 protein is considered a single
immunoreactive band around 75 kDa by western-blot analysis but several reports have
revealed the existence of multiple MeCP2 immunoreactive bands above and below the
level where MeCP2 is expected. MeCP2 immunoreactive bands have been interpreted in
different ways. Some researchers suggest that multiple MeCP2 immunoreactive bands are
unidentified proteins that cross-react with the MeCP2 antibody or degradation product of
MeCP2, while others suggest that MeCP2 post-transcriptional processing generates multi-
ple molecular forms linked to cell signaling, but so far they have not been properly analyzed
in relation to Rett syndrome experimental models. The purpose of this study is to advance
understanding of multiple MeCP2 immunoreactive bands in control neural cells and p.
T158MMeCP2e1 mutant cells. We have generated stable wild-type and p.T158M
MeCP2e1-RFP mutant expressing cells. Application of N- and C- terminal MeCP2 antibod-
ies, and also, RFP antibody minimized concerns about nonspecific cross-reactivity, since
they react with the same antigen at different epitopes. We report the existence of multiple
MeCP2 immunoreactive bands in control cells, stable wild-type and p.T158MMeCP2e1-
RFP mutant expressing cells. Also, MeCP2 immunoreactive bands differences were found
between wild-type and p.T158MMeCP2e1-RFP mutant expressing cells. Slower migration
phosphorylated band around 70kDa disappeared in p.T158MMeCP2e1-RFP mutant
expressing cells. These data suggest that threonine 158 could represent an important phos-
phorylation site potentially involved in protein function. Our results clearly indicate that
MeCP2 antibodies have no cross-reactivity with similar epitopes on others proteins, sup-
porting the idea that MeCP2 may exist in multiple different molecular forms and that molecu-
lar pattern variations derived from altered post-transcriptional processing may underlay Rett
syndrome physiophatology
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Introduction
Methyl-CpG-binding protein 2 (MeCP2) was initially identified in 1992 as a classic methyl-
CpG-binding protein [1]. The knowledge about MeCP2 protein function has changed over
time, from being considered a single function protein [2] to a multifunctional nuclear protein
[3]. Dysfunctions of human MeCP2 protein (hMeCP2) lead to various neurological disorders
[4] such as Rett syndrome [5] and Autism [6]. In human and mouse, MeCP2 exists in two dif-
ferent isoforms produced by alternative splicing differing at the N-termini due to exclusion or
inclusion of exon 2 respectively. Conventional western-blot analysis would not allow resolution
of the two MeCP2 isoforms [7,8].
The exact functions of MeCP2 protein is still far from clear. At a molecular level, there exist
contradictory data. MeCP2 protein is considered a single MeCP2 immunoreactive band
around 75 kDa by western-blot analysis [9] but several reports have revealed the existence of
multiple MeCP2 immunoreactive bands above and below the level where MeCP2 is expected.
Higher molecular weight form of hMeCP2 has been reported to be expressed in human frontal
cortex nuclear and synaptic fractions and in lymphoid cells as well [10]. Lower molecular
weight form of MeCP2 has been reported in rat brain nuclear extract [1,11], wild-type and
mutant mouse brain [12–15] and MeCP2 transfected cells [16]. Higher and lower molecular
weight form of hMeCP2 has been reported to be expressed in fibroblast and lymphoblastoid
strains from females with clinically diagnosed Rett syndrome [17] and MeCP2 transfected
cells [18].
Multiple MeCP2 immunoreactive bands have been interpreted in different ways. Some
researchers suggest that multiple MeCP2 immunoreactive bands are unidentified proteins that
cross-react with the MeCP2 antibody [11,12,15–17] or degradation product of MeCP2 [1,14],
while others suggest that hMeCP2 post-transcriptional processing generates multiple molecu-
lar forms linked to cell signaling [10,18].
In addition, many MeCP2 antibodies available commercially against different epitopes of
MeCP2 protein detected multiple bands by western-blot analysis (Table 1).
The purpose of this study is to advance understanding of MeCP2 multiple immunoreactive
bands in wild-type and MeCP2 mutant neural cells. In the present study, we found that immu-
noblots of whole several control neural cell lines lysates revealed the existence of multiple
MeCP2 immunoreactive bands above and below the level where MeCP2 is expected.
To test the specificity of MeCP2 antibodies, we have generated stable wild-type and p.
T158MMeCP2e1-red fluorescence protein (RFP) fusion protein mutant expressing neural
cells. Application of N- and C- terminal MeCP2 antibodies, and also, RFP antibody minimized
concerns about nonspecific cross-reactivity, since they react with the same antigen at different
epitopes.
No large differences in the apparent molecular weight (MWa) of MeCP2 immunoreactive
bands were noticed between control neural cells and hMeCP2e1-RFP stable transfected neural
cell lines. In addition, staining with RFP antibody, that minimized concerns about nonspecific
cross-reactivity, produced blots with similar pattern. Futhermore, no large differences in the
apparent molecular weight of MeCP2 immunoreactive bands were noticed between our results,
previous reports and MeCP2 antibodies available commercially against different epitopes of
MeCP2 protein.
To demonstrate the specificity of multiple MeCP2 immunoreactive bands detected in
hMeCP2e1-RFP expressing neural cell lines, and therefore, definitely exclude the cross-reactiv-
ity with similar epitopes on other proteins, we performed MeCP2e1-RFP+ protein detection via
SDS-PAGE and in-gel fluorescence scanning. After the fluorescence scan, proteins in gels were
transferred to nitrocellulose membranes for western blotting. The immunoblot with antibody
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against MeCP2 revealed multiple MeCP2 immunoreactive bands at the same position as the
fluorescent signals.
Lastly, MeCP2 immunoreactive bands differences were found between stable wild-type and
p.T158MMeCP2e1-RFP mutant expressing neural cells. Slower migration phosphorylated
band around 70kDa disappeared in p.T158MMeCP2e1-RFP mutant expressing cells. These
data suggest that threonine 158 could represent an important phosphorylation site potentially
involved in protein function.
Our results clearly indicate that MeCP2 antibodies have no cross-reactivity with similar epi-
topes on others proteins, supporting the idea that MeCP2 may exist in multiple different
molecular forms and that molecular pattern variations derived from altered post-transcrip-
tional processing may underlay Rett syndrome physiophatology
Materials and Methods
Cell Culture
Human embryonic kidney HEK293 (ATCC No. CRL-1573) cell line, human neuroblastoma
SH-SY5Y (ATCC No. CRL-2266) cell line and murine neuroblastoma Neuro-2A (N2A; ATCC
No. CCL-131) cell line were maintained in a growth medium Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum, 100 units/ml penicillin-strepto-
mycin and 2 mM L-glutamine. Rat pheochromocytoma PC12 (ATCC No. CRL-1721) cell line
was maintained in a growth medium (DMEM) supplemented with 5% fetal bovine serum, 10%
horse serum, 100 units/ml penicillin-streptomycin and 2 mM L-glutamine. The cell lines were
incubated at 37°C in 5% CO2. All cell cultured reagents were from Sigma-Aldrich (St. Louis,
MO, USA).
Table 1. MeCP2 antibodies available commercially against different epitopes of MeCP2 protein detectedmultiple bands by western-blot analysis.
Name of antibody Comercial supplier MeCP2 Immunogen Species isotype Aproximate sizes (KDa)
Ab137358 Abcam a.a.1-232 Rabbit IgG 95,70
Ab117567 Abcam a.a.1-486 Mouse IgG 95,75,50,40
Ab50005 Abcam a.a.471-486 Mouse IgG 75,50
Ab2829 Abcam a.a.469-486 Rabbit IgG 55,40
Ab119955 Abcam a.a.2-211 Rabbit IgG 55,34
Ab75716 Abcam a.a. surrounding S421 Rabbit IgG 75,55,40
SAB2101453 Sigma-Aldrich a.a.36-85 Rabbit IgG 95,40
HPA000593 Sigma-Aldrich a.a.239-350 Rabbit IgG 50,70,30
WH0004204M1 Sigma-Aldrich a.a.81-170 Mouse IgG 75,50
OAAB15948 Avivasybio a.a.3-33 Rabbit IgG 95,75,50,40
ARP32694P050 Avivasybio a.a.35-84 Rabbit IgG 95,45
OAPC00174 Avivasybio a.a. surrounding S80 Rabbit IgG 75,50
H00004204-M01 Abnova a.a.81-170 Mouse IgG 95,75,50,40
H00004204-D01P Abnova a.a.1-486 Rabbit IgG 75,50
SC-137070 Santa Cruz a.a.185-486 Mouse IgG 90,55
SC-5755 Santa Cruz N-terminus Rabbit IgG 90,75,55
PA5-12234 Thermoﬁsher a.a.400-408 Rabbit IgG 75,55,40
PA1-887 Thermoﬁsher a.a.1-15 Rabbit IgG 55,40
ABE28 Merck-Millipore a.a.1-486/K464-ac Rabbit IgG 110,80,50
ABE171 Merck-Millipore a.a.1-486 Chicken IgY 100,80,70,40
doi:10.1371/journal.pone.0153262.t001
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Generation of wild type and p.T158M hMeCP2e1-mRFPmutant fusion
proteins
We used human cDNA clones (Genebank:BQ072357 and Genebank:BC011612.1) as template
to generate full lenght hMeCP2e1 coding sequence. The PCR products were inserted into
pSTBlue1 vector (Millipore, Billerica, MA, USA). hMeCP2e1 coding region without stop
codon was subcloned into the pSTBlue1-mRFP vector to obtain hMeCP2e1-RFP in-frame
fusion protein. Mutant hMeCP2e1-RFP (p.T158M) was generated using QuickChange II site-
directed mutagenesis Kit1 (Angilent Technologies, Santa Clara, CA, USA). We used the
pSTBlue1-hMeCP2e1-RFP as template and the following primers:
hMeCP2e1T158M/se
5'GACCCTAATGATTTTGACTTCATGGTAACTGGGAGAGGGAGCCCC3'.
hMeCP2e1T158M/as
5'GGGCTCCCTCTCCCAGTTACCATGAAGTCAAAATCATTAGGGTCC3'.
Wild-type and mutant hMeCP2e1-RFP fusion protein were subcloned into pIRES1hyg
bicistronic expression vector (Clontech, Cambridge, UK). DNA fragments were identified by
restriction enzyme analysis and confirmed by double-stranded DNA sequencing.
Transfection methods
One day before transfection the cells were seeded at a density of 0.5x105 cells/cm2 in multi-well
(12 or 24-well) plates. The cells were incubated with Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA), for 4 hours (following the supplier’s instructions), after which the lipofection mix
was removed and replaced with fresh medium. Drug selection of stable transfectants was per-
formed with 50–100 mg/ml hygromycin B (hyg; Calbiochem, La Jolla, CA, USA).
Western Blotting
Cell lines were harvested using trypsin/EDTA (Gibco), washed twice with PBS, resuspended in
RIPA lysis buffer (Millipore, Temecula, CA, USA) for 30 min at 4°C in the presence of protease
inhibitors (Pierce™ protease inhibitor Mini Tables, Pierce Biotechnology Inc, Illinois, USA),
PMSF 1M (Abcam, Cambridge, UK) and in the presence-absence of phosphatase inhibitor
(PhosSTOP, Sigma-Aldrich). Protein concentration was determined using the bradford protein
assay (Sigma-Aldrich). Proteins were separated in a 8% SDS-polyacryamide gel (SDS-PAGE)
and transferred to a nitrocellulose membrane (Whatman, Maidstone, Kent, UK). PageRuler™
Prestained Protein Ladder (Thermo Scientific, Grand Island, NY, USA) has been used as size
standards in protein electrophoresis (SDS-PAGE) and western-blotting. After transfer, nitrocel-
lulose membranes were stained with Ponceau S solution (Sigma-Aldrich) to visualize protein
bands. Blots were then incubated over-night at 4°C with rabbit antibody against MeCP2 (H-
300,1:1000, Santa Cruz, Santa Cruz, CA, USA), rabbit antibody against RFP (PM005; 1:1000,
MBL International Corporation, Woburn, MA, USA), mouse antibody against MeCP2
(AAH11612, Sigma-Aldrich) and mouse antibody against β-actin (A5441, 1:10000; Sigma-
Aldrich). Secondary antibodies were used at 1:7000 for peroxidase anti-mouse Ab (PI-2000,
Vector Laboratories, Burlingame, CA, USA) and 1:5,000 for peroxidase anti-rabbit Ab (PI-1000,
Vector Laboratories). Immunoreactivity was detected using the enhanced chemiluminescence
(ECL) Western blot detection system (Amersham Biosciences Europe, Freiberg, Germany) and
Luminata™ Forte (Millipore corporation) using ImageQuant LAS 500 Gel Documentation Sys-
tem (GE Healthcare, Little Chalfont, UK) and G:Box Gel Documentation System (Syngene,
Cambridge, UK).
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Fluorescence analyses
Photography of fluorescent cells were carried out in an inverted Leica CTR 6000 microscope
equipped with a digital camera Leica DC500 or Leica DM IRB microscope equipped with a dig-
ital camera Leica DFC350FX (Leica Microsystems, Wetzar, Germany). In-gel fluorescence
scanning was performed on a Typhoon FLA 9500 scanner (GE Healthcare, Little Chalfont,
UK) using 432 nm excitation laser and 610 BP40 emmision filter.
Results
Multiple MeCP2 immunoreactive bands in neural cells
As noted in the introduction, the purpose of this study is to advance understanding multiple
MeCP2 immunoreactive bands above and below the level where MeCP2 is expected. To assess
MeCP2 expression at the protein level, immunoblot analysis with antibodies against the N-ter-
minal (AAH11612, a.a.93-182) and C-terminal region (H300, a.a.198-496) of hMeCP2 protein
(Fig 1A) was carried out on total cell lysate from proliferating human and murine neural cell
lines (Fig 1B). HEK293 cell line may be neuronal in origin [19].
Staining with the N-terminal MeCP2 antibody, the MWa of immunoreactive bands in PC12
cells was around 70 kDa, 55kDa and 35 kDa, while with C-terminal MeCP2 antibody, the
MWa of immunoreactive bands was around 70kDa and 40kDa (two bands) (Fig 1C).
Staining with the N-terminal MeCP2 antibody, the MWa of immunoreactive bands in N2A
cells was around 95 kDa, 70kDa (two bands), 55kDa and 35 kDa (two bands), while with C-ter-
minal MeCP2 antibody, the MWa of immunoreactive bands was around 95kDa, 70kDa, 55kDa
and 40kDa (Fig 1C).
Staining with the N-terminal MeCP2 antibody, the MWa of immunoreactive bands in
HEK293 cells was around 95kda, 70kDa and 40kDa, while with C-terminal MeCP2 antibody,
the MWa of immunoreactive bands was around 95kDa, 70kDa, 55kDa and 40kDa (Fig 1C).
Staining with the N-terminal MeCP2 antibody, the MWa of immunoreactive bands in
SHSY5Y cells was around 70 kDa, 55kDa, 40kDa and 35kDa (two bands), while with C-termi-
nal MeCP2 antibody, the MWa of immunoreactive bands was around 95kDa, 70kDa, 55kDa
and 40kDa (Fig 1C).
Multiple MeCP2 and RFP immunoreactive bands in hMeCP2e1-RFP
expressing neural cells
To test the specificity of MeCP2 antibodies, we have generated hMeCP2e1-RFP expression vec-
tor (as described in Methods). This fusion protein can be detected with MeCP2 and RFP anti-
bodies. Application of MeCP2 and RFP antibodies minimized concerns about nonspecific
cross-reactivity, since they react with the same antigen at different epitopes. Neural cell lines
were transfected by lipofection using the p(hMeCP2e1-RFP)IRES1hyg plasmid vector (as
described in Methods). hMeCP2e1-RFP transfected cells, after months of continuous drug
selection, rendered vigorously growing cultures in which most of cells were fluorescent under
the microscope (Fig 2A). Previous immunofluorescence studies have shown strong localization
of MeCP2 to methaphase chromosomes in mitotic nuclei [1] and also to pericentric hetero-
chromatin in the mouse, whereas more diffuse staining is seen in human interphase nuclei
[20]. hMeCP2e1-RFP fusion protein was correctly localized in proliferating neural cell lines
(Fig 2B and 2C).
To assess MeCP2 expression at the protein level, immunoblot analysis with antibodies
against the N-terminal (AAH11612, a.a.93-182) and C-terminal region (H300, a.a.198-496) of
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MeCP2 protein, and also, antibody against RFP (Fig 3A) was carried out on total cell lysate
from proliferating hMeCP2e1-RFP expressing neural cell lines (Fig 3B–3Q).
Staining with the N-terminal MeCP2 antibody, the MWa of immunoreactive bands in
hMeCP2e1-RFP+ HEK293 cells was around 95 kDa, 70 kDa and 35 kDa (two bands) (Fig 3B),
while with C-terminal MeCP2 antibody, the MWa of immunoreactive bands was around
95kDa, 70kDa, 55kDa and 40kDa (two bands) (Fig 3C). Double staining with N- and C-termi-
nal MeCP2 antibodies, the MWa of immunoreactive bands was around 95 kDa, 70 kDa (dou-
ble band), 55 kDa, 40kDa and 35 kDa (Fig 3D), while with RFP antibody, the MWa of
immunoreactive bands was around 95kDa, 70kDa (two bands), 55kDa and 40kDa (Fig 3E).
Staining with the N-terminal MeCP2 antibody, the MWa of immunoreactive bands in
hMeCP2e1-RFP+ PC12 cells was around 95 kDa, 70 kDa, 55kDa and 35 kDa (two bands) (Fig
3F), while with C-terminal MeCP2 antibody, the MWa of immunoreactive bands was around
95kDa, 70kDa, 55kDa, 40kDa and 35kDa (Fig 3G). Double staining with N- and C-terminal
MeCP2 antibodies, the MWa of immunoreactive bands was around was around 95 kDa, 70
kDa, 55 kDa, 40kDa and 35 kDa (Fig 3H), while with RFP antibody, the MWa of immunoreac-
tive bands was around 95kDa (two bands), 70kDa (two bands), 55kDa and 35kDa (Fig 3I).
Staining with the N-terminal MeCP2 antibody, the MWa of immunoreactive bands in
hMeCP2e1-RFP+ N2A cells was around 95 kDa, 70 kDa (two bands), 55 kDa and 40kDa (Fig
3J), while with C-terminal MeCP2 antibody, the MWa of immunoreactive bands was around
95kDa, 70kDa (three bands) and 40kDa (Fig 3K). Double staining with N- and C-terminal
MeCP2 antibodies, the MWa of immunoreactive bands was around was around 95 kDa, 70
kDa, 55 kDa, 40kDa and 35 kDa (Fig 3L), while with RFP antibody, the MWa of immunoreac-
tive bands was around 95kDa, 70kDa (two bands), 55kDa, 40kDa and 35kDa (Fig 3M).
Fig 1. Multiple MeCP2 immunoreactive bands in neural cell lines. (A) Diagram of the hMeCP2e1 protein
illustrating the position of the MeCP2 antibodies. (B) Phase-contrast photomicrographs (PhC) of proliferating
neural cell lines. Scale bar = 100μm. (C) Western-blot analysis of proliferating neural cell lines with antibodies
against the N-terminal (AAH11612, a.a.93-182) and C-terminal region (H300, a.a.198-496) of MeCP2
protein. Blots were stained with Ponceau solution as a loading control. Protein size markers (in kilodaltons)
are indicated on the side of each panel.
doi:10.1371/journal.pone.0153262.g001
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Staining with the N-terminal MeCP2 antibody, the MWa of immunoreactive bands in
hMeCP2e1-RFP+ SHSY5Y cells was around 95 kDa (doble band), 70 kDa (three bands), 55
kDa and 40kDa (Fig 3N), while with C-terminal MeCP2 antibody, the MWa of immunoreac-
tive bands was around 95kDa, 70kDa (two bands) and 40kDa (Fig 3O). Double staining with
N- and C-terminal MeCP2 antibodies, the MWa of immunoreactive bands was around was
around 95 kDa, 70 kDa, 55 kDa, 40kDa and 35 kDa (Fig 3P), while with RFP antibody, the
MWa of immunoreactive bands was around 95kDa, 70kDa (two bands), 55kDa and 40kDa
(Fig 3Q).
No large differences in the MWa of multiple MeCP2 immunoreactive bands were noticed
between control cells and hMeCP2e1-RFP stable transfected neural cell lines although the
intensity of MeCP2 and RFP immunoreactive bands sometimes varied from one experiment to
another. Application of N- and C- terminal MeCP2 antibodies, and also, RFP antibody mini-
mized concerns about nonspecific cross-reactivity, since they react with the same antigen at
different epitopes.
Lastly, to demonstrate the specificity of multiple MeCP2 immunoreactive bands detected
in hMeCP2e1-RFP expressing neural cell lines, and therefore, definitely exclude the cross-
reactivity with similar epitopes on other proteins, we performed MeCP2e1-RFP detection via
SDS-PAGE and in-gel fluorescence scanning (Fig 4). The scanning was performed on a
Typhoon FLA 9500 scanner using 432 nm excitation laser and 610 BP40 emmision filter. After
the fluorescence scan (Fig 4A, 4B and 4E), proteins in gels were transferred to nitrocellulose
membranes and stained with Ponceau solution (Fig 4C and 4F). Immunoblot analysis with
antibody against the C-terminal region of MeCP2 protein (H300, a.a.198-496) revealed
Fig 2. Correct localization of hMeCP2e1-RFP fusion protein in stable transfected neural cell lines. (A). Photomicrographs show phase-contrast (PhC)
and fluorescence images of hMeCP2e1-RFP+ expressing neural cell lines. Scale bar = 100μm. (B) Nuclear localization of hMeCP2e1-RFP in mouse and
human interphase nuclei. Scale bar = 100μm. (C) hMeCP2e1-RFP fusion protein localized to metaphase chromosomes in mitotic nuclei. Scale bar = 50μm.
doi:10.1371/journal.pone.0153262.g002
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Fig 3. Multiple MeCP2 and RFP immunoreactive bands in hMeCP2e1-RFP expressing neural cell lines.
(A) Diagram of the hMeCP2e1-RFP protein illustrating the position of the MeCP2 and RFP antibodies. (B-D)
Western-blot analysis of hMeCP2e1-RFP+ HEK293 cell line with antibodies against the N- and C-terminal
region of MeCP2. (E) RFP immunoreactive bands in transfected HEK293 cell line. (F-H)Western-blot
analysis of hMeCP2e1-RFP+ PC12 cell line with antibodies against the N- and C-terminal region of MeCP2.
(I) RFP immunoreactive bands in transfected PC12 cell line. (J-L)Western-blot analysis of hMeCP2e1-RFP+
N2A cell line with antibodies against the N- and C-terminal region of MeCP2. (M) RFP immunoreactive bands
in transfected N2A cell line. (N-P) Western-blot analysis of hMeCP2e1-RFP+ SHSY5Y cell line with
antibodies against the N- and C-terminal region of MeCP2. (Q) RFP immunoreactive bands in transfected
SHSY5Y cell line. Protein size markers (in kilodaltons) are indicated on the right of each panel.
doi:10.1371/journal.pone.0153262.g003
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multiple MeCP2 immunoreactive bands at the same position as the fluorescent signals (Fig 4D
and 4G).
Our data clearly indicate that MeCP2 antibodies have no cross-reactivity with similar epi-
topes on others proteins.
MeCP2 immunoreactive bands differences between wild-type and p.
T158MMeCP2e1-RFP mutant neural expressing cells
Different MeCP2 mutations have been identified in individuals with Rett syndrome (RettBase:
IRSFMECP2 Variation Database; http://mecp2.chw.edu.au). One of the most common
MECP2 mutations associated with Rett syndrome is p.T158M [21].
With the intention of determining whether wild-type and hMeCP2 mutant neural cell lines
differ in MeCP2 immunoreactive bands, we have generated p.T158MMeCP2e1-RFP mutant
fusion protein (Fig 5A and 5B). HEK293 cell line was transfected with eukaryotic expression
vector carrying mutated hMeCP2e1-RFP fusion protein (as described in Methods). Mutant
hMeCP2e1-RFP+ expressing neural cell line, after months of continuous drug selection, ren-
dered growing cultures in which most of cells were fluorescent under the microscope (Fig 5C).
The fluorescence intensity in mutant cells is lower than in wild-type cells.
To assess hMeCP2-RFP expression at the protein level, immunoblot analysis with MeCP2
and RFP antibodies (Fig 6A) was carried out on total cell lysate from proliferating wild-type
and mutant hMeCP2e1-RFP+ neural cell lines (Fig 5B and 5C). The MWa of RFP immunore-
active bands in wild-type hMeCP2e1-RFP transfected cells was around 95kDa, 70kDa (two
Fig 4. Immunoblot analysis with MeCP2 antibody revealed multiple MeCP2 immunoreactive bands at
the same position as the fluorescent signals detected via SDS-PAGE and in gel fluorescence
scanning. (A) Fluorescence pattern of total cell lysate from hMeCP2e1-RFP+ N2A neural cell line. (B,C,D)
Fluorescence pattern, Ponceau staining and MeCP2 immunoblot of total cell lysate from hMeCP2e1-RFP+
SHSY5Y neural cell line. (E,F,G) Fluorescence pattern, Ponceau staining and MeCP2 immunoblot of total
cell lysate from HEK293 and hMeCP2e1-RFP+ HEK293 cell lines. Protein ladder (M) and protein size
markers (in kilodaltons) are indicated on the right of each panel.
doi:10.1371/journal.pone.0153262.g004
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bands), 55kDa and 40kDa, while in p.T158MMeCP2e1-RFP mutant transfected neural cells
was around 95kDa, 70kDa and 55kDa. Staining with β-actin antibody (42kDa) was used as a
loading control (Fig 6B). Higher denaturing conditions obtained by boiling the samples prior
to electrophoresis did not affect the recognition of the RFP immunoreactive bands (Fig 6C).
The main difference between wild-type and p.T158MMeCP2e1-RFP mutant expressing
neural cell lines was that the latter detected less RFP immunoreactive bands. Only one immu-
noreactive band around 70kDa (faster migration band) was visible in p.T158MMeCP2e1-RFP
expressing cell line. Having repeated this experiment several times, always only one RFP
immunoreactive band around 70kDa (faster migration band) was detected in mutant (T158M)
hMeCP2e1-RFP+ cell line (Fig 6D and 6E). Staining with the C-terminal MeCP2 antibody, also
only one MeCP2 immunoreactive band around 70kDa (faster migration band) was detected in
mutant (T158M) hMeCP2e1-RFP+ cell line (Fig 6F and 6G). Blots were stained with Ponceau
solution as a loading control.
Protein phosphorylation is an important reversible posttranscriptional modification that
can modulate the function of MeCP2 protein via the addition of a phosphate group to serine,
tyrosine or threonine residues [22]. Phosphorylation often causes proteins to migrate more
slowly through acrylamide gels, therefore, the observed slower migration MeCP2 immunoreac-
tive band around 70kDa it could be due to protein phosphorylation.
To check this, hMeCP2e1-RFP+ HEK293 and N2A neural cell lines protein extraction was
carried out in the presence or absence of phosphatase inhibitor. Only one RFP immunoreactive
band around 70kDa (faster migration band) was visible in hMeCP2e1-RFP+ HEK293 and N2A
neural cell lines in the absence of phosphatase inhibitor (Fig 6H–6K). Blots were stained with
Ponceau solution as a loading control.
Fig 5. p.T158MMeCP2e1-RFPmutant expressing neural cell line. (A) Sequencing chromatogram of
hMeCP2e1-RFP expression vector. Red box indicated codon ACG (threonine). (B) Single nucleotide
mutation converting T158 to methionine (T158M). Sequencing chromatogram of mutant hMeCP2e1-RFP
expression vector. Red box indicated codon ATG (methionine). (C) Photomicrographs show phase-contrast
(PhC) and fluorescence images of wild-type and p.T158M hMeCP2e1-RFP+ mutant expressing neural cell
line. Scale bar = 100μm.
doi:10.1371/journal.pone.0153262.g005
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hMeCP2-T158M mutation occurs at threonine 158, converting it to methionine. Our data
suggest that threonine 158 could represent an important phosphorylation site potentially
involved in protein function.
Discussion
MeCP2 has been studied extensively and its functions have been expanded dramatically in the
past two decades, which has resulted in the identification of pleotropic functional properties of
this protein, however, the exact functions of MeCP2 protein is still far from clear [3,5,6,22–24].
At a molecular level, there exist contradictory data. MeCP2 protein is considered a single
MeCP2 immunoreactive band around 75kDa by western-blot analysis but several previous
reports have revealed the existence of multiple MeCP2 immunoreactive bands above and
Fig 6. Multiple MeCP2 and RFP immunoreactive bands in p.T158MMeCP2e1-RFPmutant expressing
neural cell line. (A) Diagram of the hMeCP2e1-RFP protein illustrating the position of the MeCP2 and RFP
antibodies. (B) RFP immunoreactive bands in wild-type and p.T158M hMeCP2e1-RFP+ mutant expressing
neural cell lines. Blots were also double-stained for β-actin, as a loading control. The asterisks marks β-actin
bands. (C) Higher denaturing conditions did not affect the recognition of the RFP immunoreactive bands.
(D-G) RFP and MeCP2 immunoreactive bands in wild-type and p.T158M hMeCP2e1-RFP+ mutant
expressing neural cell lines. (H-K) Only one RFP immunoreactive band around 70kDa (faster migration band)
was visible in hMeCP2e1-RFP+ HEK293 and N2A cell lines in the absence of phosphatase inhibitor. Blots
were stained with Ponceau solution as a loading control. Protein size markers (in kilodaltons) are indicated on
the right of each panel.
doi:10.1371/journal.pone.0153262.g006
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below the level where MeCP2 is expected [1,10–18]. Multiple MeCP2 immunoreactive bands
have been interpreted in different ways. Some researchers suggest that multiple MeCP2
immunoreactive bands are unidentified proteins that cross-react with the MeCP2 antibody
[11,12,15–17] or degradation product of MeCP2 [1,14], while others suggest that hMeCP2
post-transcriptional processing generates multiple molecular forms linked to cell signaling
[10,18].
Our results clearly indicate that MeCP2 antibodies have no cross-reactivity with similar epi-
topes on others proteins, supporting the idea that MeCP2 may exist in multiple different
molecular forms. We acknowledge that the definitive confirmation that MeCP2 may exist in
multiple molecular forms will be provided only by direct amino acid sequencing of MeCP2
immunoreactive bands (currently under way) but several data suggest it.
Firstly, as noted before, previous reports have revealed the existence of multiple MeCP2
immunoreactive bands above and below the level where MeCP2 is expected [1,10–18].
Second, as note in the introduction, many MeCP2 antibodies available commercially against
different epitopes of MeCP2 protein detected multiple bands at various molecular weights by
western-blot analysis (Table 1).
Third, we observed the existence of multiple MeCP2 immunoreactive bands in several pro-
liferating neural cell lines. Application of N- and C- terminal MeCP2 antibodies minimized
concerns about nonspecific cross-reactivity. No large differences in the MWa of MeCP2 immu-
noreactive bands were noticed between our results, previous reports and MeCP2 antibodies
available commercially against different epitopes of MeCP2 protein.
Fourth, no large differences in the MWa of multiple MeCP2 immunoreactive bands were
detected between control neural cells and hMeCP2e1-RFP transfected neural cell lines. In addi-
tion, staining with RFP antibody, that minimized concerns about nonspecific cross-reactivity,
produced blots with similar pattern. No large differences in the MWa of MeCP2 immunoreac-
tive bands were noticed between different experiments, although the intensity of MeCP2
immunoreactive bands sometimes varied from one experiment to another.
Fifth, to demonstrate the specificity of multiple MeCP2 immunoreactive bands detected in
hMeCP2e1-RFP expressing neural cell lines, and therefore, definitely exclude the cross-reactiv-
ity with similar epitopes on other proteins, we performed MeCP2e1-RFP protein detection via
SDS-PAGE and in-gel fluorescence scanning. After the fluorescence scan, proteins in gels were
transferred to nitrocellulose membranes for western blotting. The immunoblot with antibody
against MeCP2 revealed multiple MeCP2 immunoreactive bands at the same position as the
fluorescent signals.
Lastly, we found differences in the number of MeCP2 immunoreactive bands between wild-
type and p.T158MMeCP2e1-RFP mutant expressing neural cell lines. Slower migration phos-
phorylated MeCP2 immunoreactive band around 70kDa disappeared in mutant pT158M neu-
ral cell lines.
One of the most common MECP2 mutations associated with Rett syndrome is p.T158M
[21]. MeCP2 mutation p.T158M occurs at threonine 158, converting it to methionine. Our
results suggest that this particular threonine could represent an important phosphorylation site
potentially involved in protein function.
Multiple molecular forms of MeCP2 protein with different functional protein domains and
post-transcriptional modification may explain the functional complexity of the MeCP2 pro-
tein. However, futures studies investigating the amino acid composition of MeCP2 immunore-
active bands will be required to understand the function of these putative MeCP2 molecular
forms. Although Rett syndrome phsyopathology represent one of the most frequent forms of
severe intellectual disability in females, the molecular mechanisms through which different
types of MeCP2 mutation lead to disruptions in proper brain function are not fully understood
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[3,5,6,22–24]. The lacking of phosphorylated MeCP2 in p.T158Mmutant cells may represent a
seminal data to stimulate deeper molecular studies trying understand how different conforma-
tions of MeCP2 molecular pattern regulates neuronal maturation.
Finally, since it has been proved the possibility to experimentally revert endophenotypic
manifestations in adult mouse models of Rett syndrome [25], it is important to investigate
whether the consecutive expression of MeCP2 pattern may explain the temporal pattern of
functional phenotypes of this syndrome.
Conclusions
In summary, our results clearly indicate that MeCP2 antibodies have no cross-reactivity with
similar epitopes on others proteins, supporting the idea that MeCP2 may exist in multiple dif-
ferent molecular forms and that molecular pattern variations derived from altered post-tran-
scriptional processing may underlay Rett syndrome physiophatology
Finally, one of the most commonMECP2 mutations associated with Rett syndrome is p.
T158M. hMeCP2-T158Mmutation occurs at threonine 158, converting it to methionine. Our
data suggest that threonine 158 could represent an important phosphorylation site potentially
involved in protein function.
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